A study from the Abramson Family Cancer Research Institute, Philadelphia, USA; and Howard Hughes Medical Institute, Philadelphia, USA shows that “Fructose-1,6-bisphosphatase opposes renal carcinoma progression.”
This study was published in the September issue of 2014 Nature by Prof. M. Celeste Simon, Li B0 [I.F >42] and others from the Abramson Family Cancer Research Institute, Philadelphia, USA, Howard Hughes Medical Institute, Philadelphia, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Natural product-based cancer therapeutics: Luteolin, a flavone with an antioxidant and anti-inflammatory activity, increases the expression of gluconeogenic enzyme Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene. This study may suggest that Luteolin, by up regulating its target gene, it may induce FBP1. Thereby, it may inhibit (1) the expression of hypoxia-inducible factor (HIF-1); (2) glycolysis; and (3) the progression of renal cell carcinoma. Together, this study suggests that pharmacological formulations encompassing “Luteolin or its analogues“ can be used in the treatment of renal cell carcinoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Natural product-based cancer therapeutics: Luteolin, a flavone with an antioxidant and anti-inflammatory activity, increases the expression of Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene, 15/September/2014, 7.20 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
